INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 53 filers reported holding INOZYME PHARMA INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,559,557 | +22.9% | 2,276,085 | +63.1% | 0.00% | – |
| Q2 2023 | $7,775,218 | +2.2% | 1,395,910 | +5.1% | 0.00% | – |
| Q1 2023 | $7,611,102 | +439.5% | 1,328,290 | -1.1% | 0.00% | – |
| Q4 2022 | $1,410,803 | -60.8% | 1,343,622 | +0.0% | 0.00% | – |
| Q3 2022 | $3,599,000 | -44.3% | 1,343,063 | -0.8% | 0.00% | – |
| Q2 2022 | $6,460,000 | +222.5% | 1,354,216 | +176.6% | 0.00% | – |
| Q1 2022 | $2,003,000 | -39.9% | 489,613 | +0.2% | 0.00% | – |
| Q4 2021 | $3,333,000 | -53.0% | 488,719 | -20.0% | 0.00% | – |
| Q3 2021 | $7,084,000 | +24.0% | 611,185 | +82.3% | 0.00% | – |
| Q2 2021 | $5,713,000 | -15.4% | 335,286 | -1.7% | 0.00% | – |
| Q1 2021 | $6,751,000 | +5.8% | 340,964 | +10.3% | 0.00% | – |
| Q4 2020 | $6,380,000 | -18.3% | 309,114 | +4.1% | 0.00% | – |
| Q3 2020 | $7,809,000 | – | 297,037 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 4,494,851 | $18,878,374 | 7.53% |
| CHI Advisors LLC | 1,270,027 | $5,334,112 | 2.11% |
| Samsara BioCapital, LLC | 1,562,500 | $6,562,500 | 2.01% |
| Affinity Asset Advisors, LLC | 1,379,852 | $5,795,378 | 1.63% |
| Sofinnova Investments, Inc. | 4,280,308 | $17,977,294 | 1.13% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,234,907 | $5,186,609 | 0.94% |
| Octagon Capital Advisors LP | 1,300,000 | $5,460,000 | 0.84% |
| NEA Management Company, LLC | 2,437,689 | $10,238,294 | 0.79% |
| Knott David M Jr | 454,008 | $1,907 | 0.73% |
| Rock Springs Capital Management LP | 3,681,174 | $15,460,931 | 0.41% |